Literature DB >> 1632252

Acute laryngitis in adults: results of erythromycin treatment.

L Schalén1, I Eliasson, S Fex, C Kamme, C Schalén.   

Abstract

Previous studies of acute laryngitis in adults have shown high nasopharyngeal isolation rates of B. catarrhalis and H. influenzae. Phenoxymethylpenicillin had no effect on the clinical course. In the present study, 106 patients with acute laryngitis were treated with erythromycin 0.5 g x 2 V or placebo. During the first week the isolation rate of B. catarrhalis was reduced from 60 to 10% in the erythromycin group compared to 34 to 27% in the placebo group (p less than 0.01). The elimination of H. influenzae, isolated in 19% at the acute visit, did not differ between the two groups. As compared to controls, erythromycin treated patients reported significantly lower scores of subjective voice disturbance after 1 week and cough after 2 weeks. Laryngological examination and voice evaluation failed to reveal any differences between the groups.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632252     DOI: 10.3109/00016489209136810

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  4 in total

Review 1.  Antibiotics for acute laryngitis in adults.

Authors:  Ludovic Reveiz; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2015-05-23

2.  Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.

Authors:  D Chen; J C McMichael; K R VanDerMeid; D Hahn; T Mininni; J Cowell; J Eldridge
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

3.  Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitope.

Authors:  J C McMichael; M J Fiske; R A Fredenburg; D N Chakravarti; K R VanDerMeid; V Barniak; J Caplan; E Bortell; S Baker; R Arumugham; D Chen
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Adverse events in people taking macrolide antibiotics versus placebo for any indication.

Authors:  Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.